Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.68 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.67 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437226 | 0.89 | CXCR2 (0.65) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL4587902 | 0.88 | CXCR2 (0.67) | CXCR2CX3CR1 | |
| SCHEMBL4586753 | 0.87 | CXCR2 (0.77) | CXCR2CX3CR1 | |
| SCHEMBL6564112 | 0.87 | CXCR2 (0.65) | CXCR2CX3CR1CXCR1MEN1LMNA | |
| SCHEMBL6565712 | 0.86 | CXCR2 (0.68) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL6566318 | 0.85 | CXCR2 (0.69) | CXCR2CX3CR1CXCR1 | |
| SCHEMBL4587185 | 0.85 | CXCR2 (0.73) | CXCR2CX3CR1 | |
| SCHEMBL6565715 | 0.85 | CXCR2 (0.69) | CXCR2CX3CR1CXCR1MEN1LMNA | |
| SCHEMBL4588222 | 0.84 | CXCR2 (0.65) | CXCR2CX3CR1CXCR1MEN1LMNA | |
| SCHEMBL27571694 | 0.84 | CXCR2 (0.65) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | CXCR2 26/4885CX3CR1 91/4885CXCR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.